Annovis Bio Inc. (NYSE: ANVS) Announces New Execut
Post# of 101
(Total Views: 123)
Posted On: 07/23/2024 4:37:03 PM
Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members
- The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen
- These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market
Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team.
Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have this strong group of individuals join the Annovis team. “Their expertise and leadership are critical in this pivotal moment in our company, as we continue making strides towards bringing buntanetap closer to NDA and to market for Alzheimer’s and Parkinson’s diseases,” Maccecchini added (https://nnw.fm/Ogvax ).
Mark White, who is currently serving on the Annovis Board of Directors, has been appointed as Chief Business Officer. He brings extensive experience in global pharmaceutical marketing, business development, and sales. His career includes significant roles at Pfizer, Bracco, Abbott, and Bayer. At Pfizer, he served as Vice President of Worldwide Marketing, where he was responsible for global new product development, business development, and in-line marketing for the Inflammation Therapeutic Area. Mark holds both bachelor’s and master’s degrees from the University of Missouri, as well as an MBA from the University of Chicago Booth School of Business.
Dr. Alexander Morin joins as the Director of Strategic Communications, bringing a rich background in the biopharmaceutical industry’s science and communications sectors. Previously, he was an Account Executive at a boutique public relations firm, where he enhanced corporate communications strategies and visibility for a variety of clients, including biotech companies, non-profits, and large pharmaceutical firms. Before his PR role, Dr. Morin was a consultant scientist at a CRO, designing studies for drug candidates. He holds a Ph.D. in Neuroscience from the Open University (“UK”), with a research focus on drug development for chronic traumatic brain injury.
With over 30 years of experience, Hilda Maibach steps in as Senior Vice President of Statistics. She has extensive expertise in clinical and observational studies across Oncology, Infectious Disease, Metabolic disorders, and Central Nervous System Disorders. Her work has supported industry, NIH, and DOD-funded clinical trials, emphasizing improving measurement sensitivity and innovating clinical trial design, data acquisition, and management. Ms. Maibach has also incorporated real-world evidence and bioinformatics tools into clinical study design to reduce costs and enhance outcome reliability. Her academic background includes research faculty positions at Emory and Stanford Universities, as well as a role as a statistician at the Centers for Disease Control (“CDC”) for CLIA. She holds an MSc in Statistics from Stanford University.
Blake Jensen, with over 20 years of experience in Quality, joins Annovis Bio as the Head of Quality. His background spans work within contract service providers and emerging biopharma companies, along with his prior role as an investigator for the U.S. FDA. Mr. Jensen has developed and implemented quality systems for start-up companies as a solo QA department and has led Quality teams of up to 90 people. He has considerable experience with regulatory inspections, hosting inspections from various health authorities, conducting inspection readiness activities, mock inspections, and delivering inspection training. During his time with the FDA, he conducted BIMO and GMP inspections. In the CRO space, he has managed teams across quality risk management, global audits, vendor management, CAPA, audit and inspection defense, policy and procedure management, billable audits, and quality analytics.
Annovis Bio is excited about the new additions to its executive team and confident that these highly experienced professionals will significantly contribute to the company’s mission of developing transformative therapies for neurodegenerative diseases. The combined expertise of Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen will enhance strategic initiatives, strengthen communications, refine statistical approaches, and ensure the highest standards of quality. The company looks forward to their invaluable contributions as it continues to advance its clinical programs and strive to make a meaningful impact on the lives of patients with Alzheimer’s and Parkinson’s diseases.
For more information, visit the company’s website at www.AnnovisBio.com, and social channels
LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen
- These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market
Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team.
Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have this strong group of individuals join the Annovis team. “Their expertise and leadership are critical in this pivotal moment in our company, as we continue making strides towards bringing buntanetap closer to NDA and to market for Alzheimer’s and Parkinson’s diseases,” Maccecchini added (https://nnw.fm/Ogvax ).
Mark White, who is currently serving on the Annovis Board of Directors, has been appointed as Chief Business Officer. He brings extensive experience in global pharmaceutical marketing, business development, and sales. His career includes significant roles at Pfizer, Bracco, Abbott, and Bayer. At Pfizer, he served as Vice President of Worldwide Marketing, where he was responsible for global new product development, business development, and in-line marketing for the Inflammation Therapeutic Area. Mark holds both bachelor’s and master’s degrees from the University of Missouri, as well as an MBA from the University of Chicago Booth School of Business.
Dr. Alexander Morin joins as the Director of Strategic Communications, bringing a rich background in the biopharmaceutical industry’s science and communications sectors. Previously, he was an Account Executive at a boutique public relations firm, where he enhanced corporate communications strategies and visibility for a variety of clients, including biotech companies, non-profits, and large pharmaceutical firms. Before his PR role, Dr. Morin was a consultant scientist at a CRO, designing studies for drug candidates. He holds a Ph.D. in Neuroscience from the Open University (“UK”), with a research focus on drug development for chronic traumatic brain injury.
With over 30 years of experience, Hilda Maibach steps in as Senior Vice President of Statistics. She has extensive expertise in clinical and observational studies across Oncology, Infectious Disease, Metabolic disorders, and Central Nervous System Disorders. Her work has supported industry, NIH, and DOD-funded clinical trials, emphasizing improving measurement sensitivity and innovating clinical trial design, data acquisition, and management. Ms. Maibach has also incorporated real-world evidence and bioinformatics tools into clinical study design to reduce costs and enhance outcome reliability. Her academic background includes research faculty positions at Emory and Stanford Universities, as well as a role as a statistician at the Centers for Disease Control (“CDC”) for CLIA. She holds an MSc in Statistics from Stanford University.
Blake Jensen, with over 20 years of experience in Quality, joins Annovis Bio as the Head of Quality. His background spans work within contract service providers and emerging biopharma companies, along with his prior role as an investigator for the U.S. FDA. Mr. Jensen has developed and implemented quality systems for start-up companies as a solo QA department and has led Quality teams of up to 90 people. He has considerable experience with regulatory inspections, hosting inspections from various health authorities, conducting inspection readiness activities, mock inspections, and delivering inspection training. During his time with the FDA, he conducted BIMO and GMP inspections. In the CRO space, he has managed teams across quality risk management, global audits, vendor management, CAPA, audit and inspection defense, policy and procedure management, billable audits, and quality analytics.
Annovis Bio is excited about the new additions to its executive team and confident that these highly experienced professionals will significantly contribute to the company’s mission of developing transformative therapies for neurodegenerative diseases. The combined expertise of Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen will enhance strategic initiatives, strengthen communications, refine statistical approaches, and ensure the highest standards of quality. The company looks forward to their invaluable contributions as it continues to advance its clinical programs and strive to make a meaningful impact on the lives of patients with Alzheimer’s and Parkinson’s diseases.
For more information, visit the company’s website at www.AnnovisBio.com, and social channels
LinkedIn, X and YouTube.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Anv Sec Group Inc. (ANVS) Stock Research Links
Scroll down for more posts ▼